Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.59 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.59 |
| ▸ | ACHE | P22303 | 3/20 | 0.57 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | EDNRA | P25101 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21083860 | 1.00 | AGTR1 (0.59) | AGTR1LTB4R2ACHEABCC3ABCC4 | |
| SCHEMBL21083897 | 0.88 | AGTR1 (0.67) | AGTR1LTB4R2ACHEABCC3ABCC4 | |
| SCHEMBL21084042 | 0.83 | ACHE (0.75) | AGTR1LTB4R2ACHEABCC3ABCC4 | |
| SCHEMBL29726868 | 0.83 | ACHE (0.75) | AGTR1LTB4R2ACHEABCC3ABCC4 | |
| SCHEMBL21083829 | 0.82 | ACHE (0.56) | AGTR1LTB4R2ACHEABCC3ABCC4 | |
| SCHEMBL29726847 | 0.82 | ACHE (0.56) | AGTR1LTB4R2ACHEABCC3ABCC4 | |
| SCHEMBL21125618 | 0.81 | AGTR1 (0.77) | AGTR1LTB4R2ACHEABCC3ABCC4 | |
| SCHEMBL13539755 | 0.81 | AGTR1 (0.70) | AGTR1LTB4R2ACHEABCC3ABCC4 | |
| SCHEMBL21083916 | 0.81 | AGTR1 (0.53) | AGTR1LTB4R2ACHEABCC3ABCC4 | |
| SCHEMBL21083919 | 0.81 | AGTR1 (0.53) | AGTR1LTB4R2ACHEABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3478672-B1 | BIARYLMETHYL HETEROCYCLES | UNIV MONTREAL (CA) | 2024-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | AGTR1 7/4885LTB4R2 133/4885ACHE 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.